US Bancorp
SRPT icon

US Bancorp’s Sarepta Therapeutics SRPT Stock Holding History

US Bancorp’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.3K Sell
2,073
-1,563
-43% -$29.6K ﹤0.01% 2938
2026
Q1 		$79.1K Sell
3,636
-768
-17% -$14.9K ﹤0.01% 2501
2025
Q4 		$94.8K Buy
4,404
+896
+26% +$18.9K ﹤0.01% 2401
2025
Q3 		$67.6K Sell
3,508
-208
-6% -$3.71K ﹤0.01% 2527
2025
Q2 		$63.5K Buy
3,716
+543
+17% +$23.2K ﹤0.01% 2660
2025
Q1 		$203K Sell
3,173
-573
-15% -$60.3K ﹤0.01% 1987
2024
Q4 		$455K Sell
3,746
-2,803
-43% -$344K ﹤0.01% 1540
2024
Q3 		$818K Buy
6,549
+271
+4% +$37.5K ﹤0.01% 1230
2024
Q2 		$992K Sell
6,278
-2,137
-25% -$275K ﹤0.01% 1114
2024
Q1 		$1.09M Buy
8,415
+876
+12% +$107K ﹤0.01% 1077
2023
Q4 		$727K Buy
7,539
+1,043
+16% +$100K ﹤0.01% 1288
2023
Q3 		$787K Sell
6,496
-282
-4% -$31.9K ﹤0.01% 1152
2023
Q2 		$776K Sell
6,778
-2,099
-24% -$271K ﹤0.01% 1177
2023
Q1 		$1.22M Buy
8,877
+524
+6% +$68K ﹤0.01% 985
2022
Q4 		$1.08M Sell
8,353
-4,002
-32% -$464K ﹤0.01% 1029
2022
Q3 		$1.36M Sell
12,355
-40
-0.3% -$4.03K ﹤0.01% 926
2022
Q2 		$929K Buy
12,395
+392
+3% +$28.8K ﹤0.01% 1129
2022
Q1 		$937K Sell
12,003
-306
-2% -$23.4K ﹤0.01% 1217
2021
Q4 		$1.11M Buy
12,309
+1,519
+14% +$130K ﹤0.01% 1154
2021
Q3 		$998K Buy
10,790
+566
+6% +$43.6K ﹤0.01% 1184
2021
Q2 		$795K Buy
10,224
+1,350
+15% +$102K ﹤0.01% 1315
2021
Q1 		$663K Buy
8,874
+3,654
+70% +$337K ﹤0.01% 1357
2020
Q4 		$890K Buy
5,220
+2,781
+114% +$412K ﹤0.01% 1147
2020
Q3 		$343K Buy
2,439
+100
+4% +$15.2K ﹤0.01% 1547
2020
Q2 		$375K Sell
2,339
-12
-0.5% -$1.63K ﹤0.01% 1452
2020
Q1 		$230K Buy
2,351
+72
+3% +$8.23K ﹤0.01% 1592
2019
Q4 		$295K Sell
2,279
-183
-7% -$18.5K ﹤0.01% 1628
2019
Q3 		$186K Buy
2,462
+1,269
+106% +$150K ﹤0.01% 1840
2019
Q2 		$181K Buy
1,193
+165
+16% +$20.1K ﹤0.01% 1882
2019
Q1 		$122K Buy
1,028
+85
+9% +$10.9K ﹤0.01% 2086
2018
Q4 		$103K Buy
943
+13
+1% +$1.63K ﹤0.01% 2103
2018
Q3 		$151K Sell
930
-530
-36% -$72.5K ﹤0.01% 2019
2018
Q2 		$193K Sell
1,460
-855
-37% -$80.6K ﹤0.01% 1885
2018
Q1 		$172K Sell
2,315
-1,909
-45% -$127K ﹤0.01% 1955
2017
Q4 		$235K Buy
4,224
+1,095
+35% +$58K ﹤0.01% 1800
2017
Q3 		$142K Buy
3,129
+505
+19% +$20.2K ﹤0.01% 2040
2017
Q2 		$88K Buy
2,624
+326
+14% +$10.6K ﹤0.01% 2263
2017
Q1 		$68K Buy
2,298
+969
+73% +$30K ﹤0.01% 2333
2016
Q4 		$36K Buy
1,329
+1,209
+1,008% +$48.6K ﹤0.01% 2604
2016
Q3 		$7K Hold
120
– – ﹤0.01% 3088
2016
Q2 		$2K Hold
120
– – ﹤0.01% 3405
2016
Q1 		$2K Hold
120
– – ﹤0.01% 3380
2015
Q4 		$5K Hold
120
– – ﹤0.01% 3248
2015
Q3 		$4K Hold
120
– – ﹤0.01% 3302
2015
Q2 		$4K Hold
120
– – ﹤0.01% 3341
2015
Q1 		$2K Hold
120
– – ﹤0.01% 3446
2014
Q4 		$2K Hold
120
– – ﹤0.01% 3426
2014
Q3 		$3K Hold
120
– – ﹤0.01% 3336
2014
Q2 		$4K Sell
120
-152
-56% -$4.8K ﹤0.01% 3276
2014
Q1 		$7K Buy
272
+152
+127% +$3.88K ﹤0.01% 3129
2013
Q4 		$2K Sell
120
-2,635
-96% -$78.3K ﹤0.01% 3304
2013
Q3 		$130K Buy
+2,755
New +$106K ﹤0.01% 1914

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

US Bancorp's SRPT Position: Q2 2026 in Review

US Bancorp reduced its Sarepta Therapeutics (SRPT) stake by 43% in Q2 2026, selling an estimated $29.6K and leaving 2,073 shares worth $37.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

US Bancorp first reported a position in SRPT in Q3 2013 and has held it in 52 quarters since. The position peaked at $1.36M in Q3 2022. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • US Bancorp held 2,073 shares of Sarepta Therapeutics worth $37.3K as of Q2 2026.
  • US Bancorp sold 1,563 Sarepta Therapeutics shares in Q2 2026, an estimated $29.6K.
  • Sarepta Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2938 holding.
  • US Bancorp first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • US Bancorp's Sarepta Therapeutics position peaked at $1.36M in Q3 2022.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.